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Abstract
The dopamine D4 receptor has been shown to play key roles in certain CNS pathologies including
addiction to cigarette smoking. Thus, selective D4 ligands may be useful in treating some of these
conditions. Previous studies in our laboratory have indicated that the piperazine analog of
haloperidol exhibits selective and increased affinity to the DAD4 receptor subtype, in comparison
to its piperidine analog. This led to further exploration of the piperazine moiety to identify new
agents that are selective at the D4 receptor. Compound 27 (KiD4 = 0.84 nM) was the most potent
of the compounds tested. However, it only had moderate selectivity for the D4 receptor.
Compound 28 (KiD4 = 3.9 nM) while not as potent, was more discriminatory for the D4 receptor
subtype. In fact, compound 28 has little or no binding affinity to any of the other four DA receptor
subtypes. In addition, of the 23 CNS receptors evaluated, only two, 5HT1AR and 5HT2BR, have
binding affinity constants better than 100 nM (Ki < 100 nM). Compound 28 is a potentially useful
D4-selective ligand for probing disease treatments involving the D4 receptor, such as assisting
smoking cessation, reversing cognitive deficits in schizophrenia and treating erectile dysfunction.
Thus, further optimization, functional characterization and evaluation in animal models may be
warranted.
1. Introduction
Targeting dopamine receptors for drug development has been of interest for decades because
of their potential utility in many well-known pathological conditions.1 Initially, dopamine
receptors were classified as D1-like and D2-like for many years until it became evident that
the D1-like receptors consisted of D1 and D5 subtypes and the D2-like receptors consisted of
D2, D3 and D4 subtypes. By far, the D2-like receptors have been studied more because of
their association with clinically relevant neuropsychiatric conditions, such as schizophrenia,
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mood disorders, Parkinson’s disease and others. Each of these subtypes is now separately
associated with certain pathophysiological conditions. For example, several D2 agonists and
partial agonists have shown beneficial effects in counteracting Parkinson’s disease,
attention-deficit hyperactivity disorder and certain mood disorders2 while D2 antagonism is
associated with antipsychotic properties.
Since its cloning, the D4 receptor has attracted considerable interest. For example, early
reports indicated that D4 antagonists attenuate not only the discriminative-stimulus effects of
cocaine and methamphetamine3–4 but also morphine-induced withdrawal signs induced by
naloxone.5 More recently, there was a report that the D4 receptor antagonist, L-745,870
(Chart 1) but not PD 168,077, a selective D4 receptor agonist, attenuated nicotine-induced
reinstatement of nicotine seeking behavior.6 Thus, it would appear that the pharmacological
blockade of DAD4 may serve as a new and potentially effective treatment against relapse to
tobacco smoking. On the other hand, PD 168,077 has been shown to induce penile erection
in rats when administered in vivo, and L-745,870 was able to block this action, and thus,
confirming the D4 receptor mediated mechanism by which penile erection occured.7 This
potential could place D4 agonists in a strong position to replace the current PDE5
antagonists with a plethora of side-effects.8 In addition, D4-receptor agonists may be useful
in reversing cognitive deficits in schizophrenia.9 These demonstrated therapeutic potentials
have encouraged the search for new D4 selective ligands in our laboratories.
We have previously carried out several SAR studies that sought to identify structural entities
that demonstrate DA receptor subtype selectivity.10–12 A frequent observation in such
studies was the fact that unlike the piperidine analogs of haloperidol, the piperazine analogs
demonstrated selective and significant affinities to the D4 receptor subtype. Chart 1 displays
common D4 selective ligands with the piperazine pharmacophore. The purpose of the
current study was to further explore the piperazine ring as a pharmacophore in a search for
new entities that are selective to the D4 receptor subtype using compound 1 (Chart 1), the
piperazine analog of haloperidol as the lead.
2. Chemistry
The syntheses of compounds 1–7 (Chart 2) have previously been reported using routine N-
alkylation reactions.9 Compound 8, the cyclic analog of 1, was synthesized as depicted in
Scheme 1 below. The commercially available 4-chloro-1-(4-fluorophenyl)-butan-1-one (29)
was converted to 4-chloro-1-(4-fluorophenyl)-2-methylenebutan-1-one (30) by refluxing in
acetic anhydride in the presence of hexamethylenetriamine.10,13 Compound 30 was cyclized
by heating in concentrated sulfuric acid to produce 2-(2-chloroethyl)-5-fluoro-2,3-
dihydro-1H-inden-1-one (31) which was protected by reaction with ethylene glycol to form
the 1,3-dioxolane, 32. Alkylating 4-(4-chlorophenyl)piperazine with 32 and deprotecting the
dioxolane resulted in the formation of the desired target compound 8 (Scheme 1).
Compound 9 was similarly obtained using the desfluoro starting material 4-chloro-1-
(phenyl)butan-1-one. To obtain compound 10, the indanone 31 was deoxygenated (32)
under Clemmensen reaction conditions14 and then used to alkylate 4-(4-
chlorophenyl)piperazine (Scheme 1).
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Compounds 11–14 and 16a–c (Chart 3) were previously synthesized as a part of a drug
design effort to obtain novel antipsychotic drugs.9 In general, an appropriately substituted
phenol or benzenethiol (34) was alkylated using 3-chloropropan-1-ol (35) and the resulting
alcohol (36) was either tosylated or mesylated and then utilized in alkylating the heteroaryl
piperazine (A–C) in Scheme 2. The synthesis of compounds 15–16 followed the same
procedure reported in Scheme 2.
The syntheses of compounds 17–18 (Chart 4) were also previously reported.15 To obtain the
benzo[d]oxazole analogs, 19–22 (Chart 4, Scheme 3), 2-aminophenol was reacted with
chloroalkanoyl alkyl halide (39) to form the amide intermediate (40) which was then
cyclized using polyphosphoric acid (PPA) to obtain 2-(2-chloroalkyl)benzo[d]oxazole, 41.
Compound 41 was used to alkylate 4-chlorophenyl-1-piperazine to yield the desired target
compounds 19–22.
The synthesis of benzofuran moiety in analogs 23–26 (Chart 4), followed a literature
procedure.16 2-Iodophenol was reacted with an appropriate alkyl-1-yn-1-ol to form the
corresponding benzofuran alkanol, which was subjected to a tosylation reaction and the
resulting product was used to alkylate an appropriate aryl piperazine or a related analog to
form the target compounds as shown in Scheme 4.
Finally, the synthesis of compound 28 (Chart 4) followed the synthetic procedure previously
utilized in obtaining compound 27 (Chart 4) as shown in Scheme 5.15 Briefly, 2-
aminobenzenethiol (46) was reacted with 4-chlorobutanoyl chloride (47) to form 2-(3-
chloropropyl)-benzo[d]thiazole, 48, which was then used to alkylate 2-(piperazin-1-
yl)pyrimidine to form the desired target compound, 28.
3. Results and Discussion
Cigarette smoking is associated with major diseases including cardiovascular problems,
stroke and cancers of several organs. In fact, according to the CDC website, cigarette
smoking harms nearly every organ of the body and affects a person’s overall health.17
Quitting smoking cuts down on all risks including, cardiovascular risks, stroke, and cancers
of the lung, mouth, throat, esophagus and bladder.18 Unfortunately, smoking cessation is
difficult and often requires therapeutic interventions. And yet there have been articles
suggesting significant risks associated with some of the current pharmacological
interventions.19 Thus, a search to find new agents that could help those addicted to cigarette
smoking to quit the habit is an urgent and important public health need. Similarly, the
discovery of the selective D4 agonist, PD168,077 as having the capability of reversing
cognitive deficits in schizophrenia9 and inducing penile erection7 and hence the potential to
treat erectile dysfunction is very interesting and could provide an alternative treatment
option in place of the PDE5 antagonists with several known side-effects.8
Our laboratory’s attention has been drawn to these DAD4 receptor-mediated pathologies and
that has spurred us to mine our databases for new pharmacophores for the D4 receptor.
Previous publications from our lab have identified compounds 1–7 as having low affinities
for the D2 receptor while exhibiting selectivity for the D4 receptor among D2-like receptors.
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We have now screened these compounds at the D1-like receptors (Table 1) and the results
further demonstrate that their selectivity extends beyond the D2-like receptors and hence we
selected compound 1 as the lead agent to conduct a structure-activity relationship (SAR)
study that has led to the identification of potent and selective D4 ligands. Replacing the
carbonyl moiety in compound 1 with a sulfoxide (2), methylene (3), sulfur (4) or oxygen (5)
group/atom resulted in increasing potency at the D4 receptor with Ki values from 17.5 nM to
6.9 nM respectively while binding at other DA receptors showed no observable trends. The
sulfoxide analog resulted in the lowest affinity binding at the rest of the DA receptors while
its reduced counterpart, the sulfide (4) had moderate binding except at the D1 receptor where
its affinity binding Ki was 52 nM.
Overall, these compounds have demonstrated better selectivity toward the D4 receptor when
compared to compound 1. In particular, compound 5, the oxygen analog, not only had the
best binding at the D4 receptor, but demonstrated the highest selectivity among compounds
1–5. Further probing of the oxygen analog revealed that removing the para fluoro atom (6)
has little or no contribution to binding to the D2-like receptors while replacement of N-4 in
the piperazine ring with CH (7) resulted in a very significant increase in potency for the D2
receptor with only minimal changes elsewhere. Compound 8 was designed and synthesized
to explore the effect of restricting the carbonyl group in an indanone ring, on binding
affinity and selectivity. Indeed, this transformation resulted in one of the highest selectivities
toward the D4 receptor; the ratios for the D2/D4 and D3/D4 being 253 and 406 respectively.
Synthesis of 9, an analog of 8 but without the fluorine atom resulted in a significant decrease
in binding at all the DA subtypes including the D4 suggesting the fluorine may have some
important interaction at the binding sites for these indanones. Deoxygenation of the carbonyl
to form compound 10 however, produced only minimal changes.
The next evaluations focused on the replacement of the 4-chlorophenyl moiety. Our
previous work indicated that pyridine and pyrimidine rings impacted binding to CNS
receptors.9–12 Hence, we first explored replacing the 4-chlorophenyl moiety with the
pyridine ring in compounds 3–5 to obtain compounds 11–13 (Chart 2) and the binding
affinities are reported in Table 2. Compounds 11–13 bind with very high affinities at D4
versus D1–D3 receptors, and therefore demonstrate decreased selectivity for the D4 receptor.
Compound 14, an analog of 13 with the fluorine atom replaced with a trifluoromethyl group,
displayed significantly lower binding affinities for all DA receptors suggesting either a steric
limitation or deleterious electron withdrawing effect or both. Replacement of the pyridine
ring with 5-methyl substituted pyridine for the trio (11–13) to form compounds 15a–c were
also evaluated. Interestingly, compound 15a with the oxygen linker resulted in the most
potent analog for the D4 receptor (Ki = 1.1 nM) among the 17 compounds evaluated thus
far. In addition, it also displayed the highest selectivity for the D4 receptor when compared
with the D2 receptor. Not surprisingly, compounds 15b and 15c, the sulfur and carbon
analogs respectively, have reduced binding for the D4 receptor but retain similar affinities
for the D1–D3 receptors.
Finally in this series, compounds 16a–c, the pyrimidine analogs of 11–13 were synthesized
and evaluated. Once again the oxygen analog 16a displayed the highest potency and
selectivity for the D4R among the three analogs. The carbon analog (16c) had a similar
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binding profile at the DA subtypes as 16a although its selectivity for the D4R is much lower.
Meanwhile, the sulfur analog 16b again demonstrated a 5-fold lower affinity for the D4R
compared to 16a. These evaluations have clearly demonstrated that the oxygen analogs have
the highest potencies for the D4R within each cohort evaluated. Comparing the pyridine and
pyrimidine analogs in this series, the pyridine analogs overall, demonstrated moderate
enhancement in binding affinity at the D4R than the pyrimidine analogs. In addition, among
the twenty compounds evaluated, none has a better binding affinity for the D5 receptor than
compound 7 with a Ki of 867 nM. In other words, the compounds have little or no affinity
for the D5R.
The last group of compounds evaluated is 17 – 28 (Chart 4), which may be considered as the
heterobicyclic analogs of the compounds in charts 2 and 3, with binding affinities reported
in Table 3. Compound 17 and 18 are benzothiazole analogs which were previously
synthesized and evaluated for binding to the D2-like receptors.15 In this paper, their binding
affinities to the D1-like receptors were evaluated and the results are reported. The results
suggest that a chain length of 4 (17) produced a more potent agent at the D4R than a chain
length of 3 (18). The selectivities of both compounds for the D4R were unremarkable.
Next, we synthesized and evaluated the benzoxazole analogs, 19 – 22, by systematically
modifying the chain length from 5 to 2 respectively. A chain length of five atoms (19)
produced a weak binding affinity at the D4R (Ki = 240 nM) while 20, with a chain length of
4 atoms produced an 8-fold increase in binding to the D4 receptor (Ki = 30.6 nM), thus
suggesting a chain length of 4 is preferred. Compound 20 however, has similar affinity for
the D3R (Ki = 33 nM) resulting in loss of selectivity. Further comparison of this
benzothiazole, 20 with the benzoxazole, 17 shows over 7-fold differential, suggesting the
benzothiazole ring with a 4-methylene chain is preferred at the D4R. There is however no
preference at the D3 receptor since they (17 & 20) have similar binding affinities.
Compounds 21 and 22, benzoxazoles with a chain length of 3 and 2 respectively, resulted in
compounds with only moderate to very weak binding affinities at all the DA receptors.
We also synthesized and evaluated compounds obtained by replacement of the benzoxazole
with a benzofuran, (Chart 4), 23 – 26, of which 24 may be considered as a restricted analog
of the straight chain ether analog in Chart 2. The results indicated that while somewhat
selective for the D4 receptor, the 2 carbon chain analog (23) and the 3-chain analog (24)
have weaker binding affinities for the D4 receptor. Replacement of the piperazine ring with
its bridged counterpart (25) and with a homopiperazine (26) did not improve potency or
selectivity.
Returning to the benzothiazoles, we further explored replacement of the 4-chlorophenyl
moiety with 2-(piperazin-1-yl)pyrimidine to obtain the 4-chain (27) and 3-chain (28)
analogs. Compound 27 was the most potent D4 ligand in this study (Ki = 0.84 nM) as
previously reported15 albeit with diminished selectivity, while 28 has high potency (Ki = 3.9
nM) and is by far the most selective analog at the D4 receptor when compared with other
dopamine subtypes. Taking their binding constants at face value, compound 28 is as potent
but more selective than FAUC 113, a previously reported D4 ligand (Chart 1).20 In addition,
while not as potent as L-745,860,21 compound 28 is also more selective for the D4 receptor
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among the D2-like receptors. To determine the extent of compound 28’s selectivity, we
screened its binding affinities at several other CNS receptors and the results are reported in
Table 4.
Screening experiments involving a total of 18 other receptors indicated that apart from the
5HT1A and 5HT2B receptors, where binding affinities were below 100 nM (Ki < 100 nM),
compound 28 exhibited significantly poorer affinities for the remainder of the assayed
receptors. The above results strongly suggest that compound 28 can be a potentially useful
D4-selective ligand for probing D4R related pathophysiological conditions including
smoking cessation, erectile dysfunction and reversal of cognitive deficits in schizophrenia
depending on the intrinsic activity.
3.1. Conclusions
This study was initiated to identify selective DAD4 receptor ligands. The results confirm the
piperazine ring as a reliable pharmacophore impacting potency and selectivity for the D4
receptor. Of the 25 piperazine derivatives evaluated, all displayed higher potencies at the D4
than at the D2 receptors. Compound 27 (Ki = 0.84 nM) has the highest potency at the D4
receptor but displays only moderate selectivity compared to the other DA subtypes. The
most significant finding however is the identification of a novel benzothiazole alkyl
piperazine, compound 28, with a binding affinity constant (Ki) of 3.9 nM and no significant
binding affinity to any of the other DA receptor subtypes (less than 50% inhibition of the
appropriate radioligand at each of the other DA subtypes). In addition, compound 28 has
only weak to moderate affinities for eighteen other CNS receptors. These results warrant a
more elaborate pharmacological profiling, including functional characterization, which is the
focus of our current ongoing studies.
4. Experimental
Melting points were determined on a Gallenkamp (UK) apparatus and are uncorrected. All
NMR spectra were obtained on a Varian 300 MHz Mercury Spectrometer. Elemental
analyses were carried out by Atlantic Microlab, Inc., Norcross, GA, and are within 0.4% of
theory unless otherwise noted. Flash chromatography was performed with Davisil grade 634
silica gel. Starting materials were obtained from Sigma-Aldrich and were used without
further purification.
4.1. Synthetic Procedure
4.1.1. Synthesis of 2-(2-chloroethyl)-5-fluoro-indan-1-one, 31—A mixture of 4-
chloro-1-(4-fluorophenyl)-butan-1-one, 29 (10 g, 50 mmol), hexamethylenetriamine (10.5 g,
75 mmol) in Ac2O (25 mL) was refluxed under N2 for 16 h. After cooling to rt, the mixture
was diluted with CHCl3 (500 mL) and then washed with HCl solution (10%, 2×300 mL),
H2O (300 mL), and sat NaHCO3 (300 mL). The organic layer was dried over Na2SO4, and
filtered. The filtrate was concentrated in vacuo, followed by column chromatography on
silica gel to afford 4-chloro-1-(4-fluoro-phenyl)-2-methylene-butan-1-one, 30 (2.8 g,
26.4%). 1H NMR (CDCl3): δ 7.82 (dd, J = 9.0, 5.7 Hz, 2H), 7.13 (t, J = 9.0 Hz, 2H), 5.99 (s,
1H), 5.73 (s, 1H), 3.72 (t, J = 6.6 Hz, 2H), 2.94 (t, J = 6.0 Hz, 2H).
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Compound 30 (1.2 g, mmol) was dissolved in Conc H2SO4 (4 mL) and heated at 60°C for 1
h. After cooling to rt, the mixture was diluted with EtOAc (200 mL) and washed with sat’d
NaHCO3 (2×200 mL). The organic layer was dried over Na2SO4, and filtered. The filtrate
was concentrated under vacuum followed by column chromatography on silica gel to afford
2-(2-chloro-ethyl)-5-fluoro-indan-1-one, 31 in quantitative yield. 1H NMR (CDCl3): δ 7.76
(dd, J = 8.4, 5.4 Hz, 1H), 7.05–7.14 (m, 2H), 3.80–3.86 (m, 1H), 3.68–3.78 (m, 1H), 3.42
(dd, J = 17.1, 7.8 Hz, 1H), 2.90–2.98 (m, 1H), 2.83 (dd, J = 17.1, 4.2 Hz, 1H), 2.38–2.49 (m,
1H), 1.86–1.98 (m, 1H).
4.1.2. 2′-(2-Chloroethyl)-5′-fluoro-2′,3′-dihydrospiro[[1,3]dioxolane-2,1′-
indene], 33—A solution of 2-(2-chloro-ethyl)-5-fluoro-indan-1-one (5 g, 23.5 mmol),
ethylene glycol (5 mL), TsOH (100 mg) in toluene (50 mL) was refluxed under N2 for 48 h.
Water was removed by azeotropic distillation and the reaction was monitored by 1H NMR.
The reaction was quenched by addition of Et3N (1 mL), diluted with EtOAc (250 mL),
washed with sat NaHCO3, (25 mL), H2O (25 mL). The organic layer was dried over
Na2SO4, and filtered. The filtrate was concentrated in under vacuum to dryness yielding a
mixture of 2-(2-chloro-ethyl)-5-fluoro-indan-1-one and its ethylene acetal in a ratio of 1/4.
2-(2-chloroethyl)-5-fluoro-indan-1-one was removed by reducing to its 2-(2-chloro-ethyl)-5-
fluoro-indan-1-ol with NaBH4 in MeOH, followed by column chromatography on silica gel
which afforded 2′-(2-chloroethyl)-5′-fluoro-2′,3′-dihydrospiro[[1,3]dioxolane-2,1′-indene]
33 (4.5 g, 75%). 1H NMR (CDCl3): δ 7.24–7.28 (m, 1H), 6.89–6.96 (m, 2H), 4.22–4.28 (m,
1H), 4.07–4.16 (m, 3H), 3.70–3.74 (m, 1H), 3.62–3.68 (m, 1H), 3.55–3.61 (m, 1H), 3.07
(dd, J = 14.7, 6.6 Hz, 1H), 2.71–2.75 (m, 1H), 2.60–2.68 (m, 1H), 2.11–2.20 (m, 1H), 1.91–
2.00 (m, 1H).
4.1.3. 2-(2-(4-(4-Chlorophenyl)piperazin-1-yl)ethyl)-5-fluoro-indan-1-one
hydrochloride, 8—A mixture of 33 (1.2 g, 4.67 mmol), 1-(4-chlorophenyl)piperazine
dihydrochloride (1.3 g, 5.6 mmol), KI (100 mg), K2CO3 (1.2 g, 8.75 mmol) in DME (10
mL) was heated to reflux under N2 for 12 h. The mixture was directly purified through
column chromatography on silica gel to afford 2-{2-[4-(4-chloro-phenyl)-piperazin-1-yl]-
ethyl}-5-fluoro-indan-1-one ethylene acetal. The product was dissolved in wet MeOH and
TsOH was added with stirring at rt. After stirring at rt for 12 h, the solution was diluted with
EtOAc (450 mL) and washed with saturated NaHCO3 (40 mL). The organic layer was dried
over Na2SO4, filtered and the filtrate was concentrated in vacuo to dryness and column
chromatographed on silica gel to give 2-{2-[4-(4-chloro-phenyl)-piperazin-1-yl]-ethyl}-5-
fluoro-indan-1-one, 8. The product was converted to the hydrochloride salt and further
crystallization from MeOH-Et2O afforded the HCl salt (450 mg, yield 28%), mp 202–203
°C. 1H NMR (DMSO-d6): δ 11.15 (brs, 1H), 7.72 (dd, J = 8.7, 4.5 Hz, 1H), 7.44 (d, J = 9.0
Hz, 1H), 7.24–7.28 (m, 3H), 7.00 (d, J = 9.0 Hz, 2H), 3.77–3.80 (m, 2H), 3.53–3.56 (m,
2H), 3.28–3.36 (m, 2H), 3.12–3.22 (m, 4H), 2.81–2.90 (m, 2H), 2.22–2.78 (m, 1H), 1.84–
1.96 (m, 2H). Calcd for C21H23Cl2FN2O: C 61.62, H 5.66, N 6.84; Found: C 61.38, H 5.58,
N 6.77.
4.1.4. 2-(2-Chloroethyl)-indan-1-one—A mixture of 4-chloro-1-phenyl-butan-1-one
(10 g, 54 mmol), hexanmethylene triamine (10.5 g, 75 mmol) in Ac2O (25 mL) was refluxed
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under N2 for 18 h. After cooling to rt, the mixture was diluted with CHCl3 (500 mL) and
then washed with HCl solution (10%, 2×300 mL), H2O (300 mL), and saturated aq NaHCO3
(300 mL). The organic layer was dried over anhydrous Na2SO4, filtered and the filtrate was
concentrated in vacuo. The residue was purified by column chromatography on silica gel to
afford 4-chloro-2-methylene-1-phenyl-butan-1-one (2.8 g, 26%). 1H NMR (CDCl3): δ 7.75–
7.78 (m, 2H), 7.52–7.56 (m, 1H), 7.42–7.47 (m, 2H), 6.01 (s, 1H), 5.78 (s, 1H), 3.73 (t, J =
6.6 Hz, 2H), 2.95 (t, J = 6.6 Hz, 2H). The 4-chloro-2-methylene-1-phenyl-butan-1-one (1.2
g, 6.15 mmol) was dissolved in conc H2SO4 (4 mL) and heated at 60 °C for 1 h. The mixture
was allowed to cool to rt, diluted with EtOAc (200 mL), washed with saturated aq NaHCO3
(2×200 mL) and dried over Na2SO4. The solution was filtered, solvent was removed in
vacuo and the residue was purified by column chromatography on silica gel to afford 2-(2-
chloro-ethyl)-indan-1-one in quantitative yield. 1H NMR (CDCl3): δ 7.75 (d, J = 7.5 Hz,
1H), 7.60 (t, J = 7.2 Hz, 1H), 7.45–7.48 (m, 1H,), 7.38 (t, J = 7.2 Hz, 1H), 3.75–3.86 (m,
1H), 3.68–3.74 (m, 1H), 3.39–3.47 (m, 1H), 2.89–2.94 (m, 1H), 2.80–2.88 (m, 1H), 2.38–
2.47 (m, 1H), 1.88–1.96 (m, 1H).
4.1.5. 2-{2-[4-(4-Chloro-phenyl)-piperazin-1-yl]-ethyl}-indan-1-one tosylate, 9—
A solution of 2-(2-chloroethyl)-indan-1-one (5 g, 25.6 mmol), ethylene glycol (5 mL), p-
toluene sulfonic acid (TsOH, 100 mg) in toluene (50 mL) was refluxed under N2 for 48 h
and water was removed by azeotropic distillation. The reaction was monitored by 1H NMR
until a conversion of 80% was achieved. The reaction was quenched by the addition of Et3N
(1 mL), diluted with EtOAc (250 mL), washed with saturated aq NaHCO3, (25 mL) and
H2O (25 mL). The organic layer was dried over Na2SO4, filtered and the filtrate was
concentrated in vacuo to dryness to afford a mixture of 2-(2-chloro-ethyl)-indan-1-one and
its ethylene acetal in a ratio of 1/4. 2-(2-Chloroethyl)-indan-1-one was removed by reducing
to its 2-(2-chloro-ethyl)-indan-1-ol with NaBH4 in MeOH, followed by column
chromatography on silica gel to afford 2-(2-chloro-ethyl)-indan-1-one ethylene acetal (4.4 g,
72%). 1H NMR (CDCl3):): 7.20–7,32 (m, 4H), 4.28–4.31 (m, 1H), 4.08–4.19 (m, 3H), 3.52–
3.63 (m, 1H), 3.65–3.74 (m, 1H), 3.04–3.15 (m, 1H), 2.62–2.74 (m, 2H), 2.12–2.24 (m, 1H),
1.92–2.05 (m, 1H). A mixture of 2-(2-chloroethyl)indan-1-one ethylene acetal (1.0 g, 4.18
mmol), 1-(4-chlorophenyl)-piperazine dihydrochloride (1.4 g, 5.19 mmol), KI (100 mg),
K2CO3 (1.2 g, 8.75 mmol) in DME (10 mL) was heated to reflux under N2 for 12 h. The
mixture was allowed to cool to rt and then directly purified through column chromatography
on silica gel to afford an oily residue. Without characterization, the product was dissolved in
MeOH and p-toluene sulfonic acid (800 mg) was added with stirring at rt. After stirring for
12 h, the solution was diluted with EtOAc (450 mL) and washed with sat NaHCO3 (40 mL).
The organic layer was dried over Na2SO4, filtered and the filtrate was concentrated in vacuo
to dryness. The resulting residue was purified by column chromatography on silica gel to
afford 2-{2-[4-(4-chlorophenyl)-piperazin-1-yl]-ethyl}indan-1-one. The product was
converted to p-toluenesulfonate and crystallized in MeOH-Et2O to afford the p-
toluenesulfonate salt, 9 (610 mg, 28%). Mp 215–216 °C; 1H NMR (DMSO-d6): 9.57 (brs,
1H), 7.71 (d, J = 7.5 Hz, 1H), 7.66 (d, J = 7.2 Hz, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.47 (d, J =
8.4 Hz, 2H), 7.27 (d, J = 9.0 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), 7.01 (d, J = 9.0 Hz, 2H),
3.80–3.85 (m, 2H), 3.58–3.62 (m, 2H), 3.25–3.39 (m, 2H), 3.11–3.21 (m, 2H), 2.92–3.00
(m, 2H), 2.80–2.87 (m, 1H), 2.72–2.77 (m, 1H), 2.24 (s, 3H), 2.16–2.22 (m, 1H), 1.84–1.93
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(m, 1H). Calcd for C28H31ClN2O4S.0.8H2O: C 62.11, H 6.07, N 5.17; Found: C 62.09, H
6.06, N 5.08.
4.1.6. 2-(2-Chloroethyl)-5-fluoroindane, 32—Amalgamated zinc is prepared by
stirring a mixture of zinc (1.2 g), HgCl2 (120 mg) in H2O (5 mL) with conc HCl (0.1 mL) at
rt. After stirring for 5 min, the mixture was decanted, followed by the addition of H2O (1
mL), conc HCl (1.75 mL), toluene (10 mL), and 2-(2-chloroethyl)-5-fluoro-indan-1-one, 31
(2.0 g, 9.43 mmol). The mixture was refluxed with stirring for 12 h, allowed to cool to rt and
the solid was filtered off. The collected filtrate was diluted with EtOAc (200 mL), separated
and the organic layer was washed with H2O (50 mL) and saturated aq NaHCO3 (50 mL).
The organic layer was dried over Na2SO4, filtered and the filtrate was concentrated under
vacuum. The resulting residue was purified by column chromatography on silica gel to
afford 32 (1.68 g, 90%). 1H NMR (CDCl3): δ 7.09 (dd, J = 7.8, 4.8 Hz, 1H), 6.81–6.88 (m,
2H), 3.60 (t, J = 7.2 Hz, 2H), 3.00–3.08 (m, 2H), 2.68–2.73 (m, 1H), 2.54–2.63 (m, 2H),
1.94–2.02 (m, 2H).
4.1.7. 1-(4-Chlorophenyl)-4-(2-(5-fluoro-2,3-dihydro-1H-inden-2-
yl)ethyl)piperazine dihydrochloride, 10—A mixture of 32 (0.8 g, 4.0 mmol), 1-(4-
chlorophenyl)piperazine dihydrochloride (1 g, 4.3 mmol), KI (150 mg), K2CO3 (1.2 g, 8.7
mmol) in DME (10 mL) was heated to reflux under N2 for 12 h. The mixture was directly
purified through column chromatography on silica gel to afford 1-(4-chloro-phenyl)-4-[2-(5-
fluoro-indan-2-yl)-ethyl]-piperazine, 9. The product was converted to the hydrochloride salt
immediately and then recrystallized from MeOH-Et2O (0.78 g, 45%), mp 194–196 °C. 1H
NMR (DMSO-d6): 11.00 (brs, 1H), 7.26 (d, J = 9.0 Hz, 2H), 7.17 (dd, J = 5.7, 8.1 Hz, 1H),
6.99 (m, 3H), 6.90 (dt, J = 2.4, 8.4 Hz, 1H), 3.77 (d, J = 11.1 Hz, 2H), 3.53 (d, J = 11.1 Hz,
2H), 3.07–3.19 (m, 6H), 2.96–3.05 (m, 4H), 2.45–2.60 (m,1H), 1.88–1.96 (m, 2H). Calcd
for C21H26Cl3FN2: C 58.41, H 6.07, N 6.49; Found: C 58.56, H 6.01, N 6.49.
4.1.8. 3-(4-Fluorophenoxy)propan-1-ol, 36a—A mixture of 4-fluorophenol (1.12g, 10
mmol), 3-chloropropanol (1.4 g, 15 mmol), KI (50 mg), K2CO3 (2.76 g, 20 mmol) in iPrOH
was refluxed under N2 for 1h. The mixture was diluted with EtOAc (200 mL), washed with
H2O (50 mL) and then brine (50 mL). The organic layer was dried with Na2SO4, and
filtered. The filtrate was concentrated in vacuo, followed by distillation in vacuo to give the
intermediate, 3-(4-fluorophenoxy)propan-1-ol, 36a (1.53 g, 90%). 1H NMR (CDCl3): δ 6.96
(t, J = 8.4 Hz, 2H), 6,84 (dd, J = 9.0, 4.5 Hz, 2H), 4.09 (t, J = 6.0 Hz, 2H), 3.84–3.87 (m,
2H), 1.99–2.07 (m, 2H).
4.1.9. 3-(4-Fluorophenoxy)propyl methanesulfonate, 37a—To a solution of 36a
(1.3 g, 7.6 mmol), Et3N (3 mL) in CH2Cl2 (10 mL) was added at rt MsCl (0.8 mL, 10.3
mmol). The mixture was stirred at rt for 12 h, solvent was removed and the residue was
purified through column chromatography on silica gel, to yield 3-(4-fluorophenoxy)propyl
methanesulfonate, 37a (1.79 g, 95%). 1H NMR (CDCl3): δ 6.97 (t, J = 8.1 Hz, 2H), 6.83
(dd, J = 9.0, 4.5 Hz, 2H), 4.44 (t, J = 6.0 Hz, 2H), 4.05 (t, J = 6.0 Hz, 2H), 2.18–2.23 (m,
2H).
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4.1.10. 3-((4-Fluorophenyl)thio)propan-1-ol, 36b—A mixture of 4-fluorobenzenthiol
(1.55g, 12.1 mmol), 3-chloropropanol (2.26 g, 27.65 mmol), KI (100 mg), K2CO3 (3.3 g,
23.9 mmol) in iPrOH (10 mL) was refluxed under N2 for 1h. The mixture was diluted with
EtOAc (200 mL), and washed with water (50 mL), brine (50 mL). The organic layer was
dried with Na2SO4, and filtered. The filtrate was concentrated in vacuo, and followed by
distillation in vacuo to give product 3-(4-fluorophenylthio)propan-1-ol, 36b (1.62 g,
72%). 1H NMR (CDCl3): δ 7.35 (dd, J = 8.4, 5.4 Hz, 2H), 6.99 (t, J = 8.4 Hz, 2H), 3.76 (t, J
= 6.0 Hz, 2H), 2.98 (t, J = 7.2 Hz, 2H), 1.80–1.89 (m, 2H).
4.1.11. 3-(4-Fluorophenylthio)propyl-4-methylbenzenesulfonate, 37b—To a
solution of 3-(4-fluorophenylthio)-propan-1-ol (1 g, 5.4 mmol), Et3N (2 mL)in CH2Cl2 (10
mL) was added at rt TsCl (1.54 g, 8.1 mmol). The mixture was stirred at room temperature
for 12 h, and then followed by directly purification through column chromatography on
silica gel, and provided 3-(4-fluorophenylthio)propyl 4-methylbenzenesulfonate (1.72 g,
94%). 1H NMR (CDCl3): δ 7.77 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.30 (dd, J =
5.4, 8.4 Hz, 2H), 6.97 (d, J= 8.7 Hz, 2H), 4.13 (t, J = 8.0 Hz, 2H), 2.86 (t, J = 7.2 Hz, 2H),
1.85–1 92 (m, 2H).
4.1.12. 3-(4-Fluorophenylthio)propyl methanesulfonate, 37c—To a solution of 3-
(4-fluorophenylthio)propan-1-ol (1.2 g, 6.45 mmol), Et3N (3 mL) in CH2Cl2 (10 mL) was
added at rt MsCl (1 mL, 12.7 mmol). The mixture was stirred at room temperature for 12 h,
and then followed by directly purification through column chromatography on silica gel, and
provided 3-(4-fluorophenylthio)propyl methanesulfonate (1.60 g, 94%). 1H NMR (CDCl3):
δ 7.37 (dd, J = 9.0, 4.8 Hz, 2H), 7.00 (t, J = 9.0 Hz, 2H), 4.30 (t, J = 8.0 Hz, 2H), 3.00 (s,
3H), 2.78 (t, J = 7.2 Hz, 2H), 1.99–2.04 (m, 2H).
4.1.13. General procedure of alkylation of arylpiperazines, 15a–c—A mixture of
aryl piperazines (0.4 mmol, 1 eq.) and K2CO3 (4 mmol, 4 eq.) was stirred and refluxed for
20 min in CH3CN (10 mL). To the mixture, a solution of substituted tosylsulfonates/
mesylates/chlorides (0.53 mmol, 1.3 eq.) in CH3CN (5 mL) was added drop wise. The
reaction mixture was refluxed overnight, diluted with EtOAc (100 mL), filtered and washed
with brine. The organic layer was collected, dried (Na2SO4), filtered, and the solvent was
evaporated. The residue obtained was chromatographed on a silica gel column using hexane
and EtOAc combinations as eluent. The final compounds were obtained in moderate yields,
converted to HCl salts where necessary and re-crystallized using appropriate solvents.
4.1.14. 1-(3-(4-Fluorophenoxy)propyl)-4-(5-methylpyridin-2-yl)piperazine, 15a—
Yield 30 %, mp 79.6 °C. 1H NMR (CDCl3): δ 8.02 (s, 1H), 7.32 (dd, J = 8.7, 2.4 Hz, 1H,),
6.99–6.93 (m, 2H), 6.85–6.81 (m, 2H), 6.59 (d, J = 8.7 Hz, 1H,), 4.00 (t, J = 6.6 Hz, 2H,),
3.52–3.48 (m, 4H), 2.61–2.55 (m, 6H), 2.19 (s, 3H), 2.05–1.96 (m, 2H). 13C NMR (CDCl3):
δ 158.74, 158.03, 155.59, 155.07, 155.04, 147.67, 138.41, 122.45, 115.90, 115.60, 115.46,
115.35, 107.03, 66.75, 55.23, 53.04, 45.60, 26.65, 17.34. Calcd for C19H24FN3O: C 69.28,
H 7.34, N 12.76; Foun: C 69.47, H 7.30, N 12.50.
Sampson et al. Page 10























15b—Yield 62 %, mp 85.5 °C. 1H NMR (CDCl3): δ 8.00 (d, J = 2.4 Hz, 1H,), 7.37–7.29
(m, 3H), 7.01–6.96 (m, 2H), 6.58 (d, J = 8.7 Hz, 1H), 3.48–3.45 (m, 4H), 2.92 (t, J = 7.5 Hz,
2H), 2.54–2.46 (m, 6H), 2.18 (s, 3H), 1.86–1.77 (m, 2H). 13C NMR (CDCl3): δ 163.32,
160.06, 158.04, 147.65, 138.40, 132.20, 132.09, 122.41, 116.14, 115.85, 107.01, 105.00,
57.12, 53.01, 45.62, 32.86, 26.39, 17.34. Calcd for C19H24FN3S: C 66.05, H 7.00, N 12.16;
Found: C 66.06, H 7.03, N 12.13.
4.1.16. 1-(4-(4-Fluorophenyl)butyl)-4-(5-methylpyridin-2-yl)piperazine, 15c—
Yield 22 %, mp 74 °C 1H NMR (CDCl3) δ 8.01 (d, J = 2.7 Hz, 1H,), 7.29 (dd, J = 8.7, 2.7
Hz, 1H), 7.14–7.09 (m, 2H), 6.98–6.92 (m, 2H), 6.58 (d, J = 8.7 Hz, 1H), 3.50–3.46 (m,
4H), 2.63–2.52 (m, 6H), 2.42–2.37 (m, 2H), 2.18 (s, 3H), 1.68–1.50 (m, 4H). 13C
NMR(CDCl3): δ 162.78, 159.56, 158.11, 147.67, 138.39, 137.97, 137.93, 129.72, 129.62,
122.37, 115.12, 114.84, 106.99, 58.59, 53.09, 45.65, 34.98, 29.51, 26.34, 17.35. Calcd for
C20H26FN3: C 73.36, H 8.00, N 12.83; Found: C 73.79, H 8.28, N 12.47.
4.1.17. General Procedure for the synthesis of n-chloro-N-(2-hydroxy-
phenyl)alkylamide, 40, (n=2–5)—For n=2, a solution of 2-aminophenol (1.0 g, 9.16
mmol), 3-chloropropionylchloride, (1.39 g, 11 mmol, 1.2 eq) and Et3N (1.12 g, 11 mmol,
1.2 eq) in EtOAc (25 mL) was heated to reflux for 6–10 h. After allowing to cool to rt,
EtOAc (100 mL) was added and the solution was washed once with 10% HCl (100 mL).
The aqueous layer was extracted with EtOAc (3×100 mL) and the combined organic layers
was dried over anhydrous Na2SO4 and concentrated by rotary evaporation under reduced
pressure. The pure product, 3-chloro-N-(2-hydroxyphenyl)propanamide, 40 was obtained as
a colorless solid by column chromatography using EtOAc: hexane (3:7) as eluent.
4.1.18. General procedure for the synthesis of (n-chloroalkyl)benzoxazole, 41,
(n = 2–5)—A mixture of 3-chloro-N-(2-hydroxyphenyl)-propanamide (1g, 5.01 mmole)
and polyphosphoric acid (PPA, 3g) was heated with magnetic stirring at 130 °C for 3–4 h.
The reaction mixture was poured into ice-water (50 mL), neutralized with saturated aq NH3,
and extracted with EtOAc (2 × 50 mL). The combined extract was washed with H2O, brine,
dried (Na2SO4), and concentrated to give the crude product which was purified by column
chromatography using EtOAc: hexane (1:9) to give 2-(2-chloroethyl)benzoxazole as a pale
yellow oily liquid.
4.1.19. General procedure for the synthesis of 2-{2-[4-(4-chloro-phenyl)-
piperazin-1-yl]-ethyl}-benzoxazole—A mixture of 2-(2-chloroethyl)benzoxazole, (100
mg, 0.55 mmol), 4-chlorophenyl-piperazine, (108 mg, 0.55 mmol), and K2CO3 (433 mg,
3.30 mmol) in CH3CN (3 mL) was heated at reflux for 12–24 h. After cooling to rt, the
solvent was removed under vacuum, H2O (10 mL) was added and the solution was extracted
with EtOAc (3×50 mL). The pooled organic layer was washed with brine, dried over
Na2SO4 and concentrated by rotary evaporation at reduced pressure. The residue was
purified by column chromatography using EtOAc:hexane (9:1) as eluent to yield the pure
product (2-{2-[4-(4-chlorophenyl)piperazin-1-yl]-ethyl}benzoxazole) as a colorless solid.
The other benzoxazoles were similarly prepared.
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Yield 45%, mp 110–112 °C 1H NMR (CDCl3): δ 7.68–7.65 (m, 1H), 7.50–7.46 (m, 1H),
7.31–7.28 (m, 2H), 7.19 (d, J = 9.3 Hz, 2H), 6.82 (d, J = 9.3 Hz, 2H), 3.17–3.13 (m, 4H),
2.95 (t, J = 7.5 Hz, 2H), 2.59–2.56 (m, 4H), 2.40 (t, J = 7.5 Hz, 2H), 1.98–1.91 (m, 2H),
1.66–1.58 (m, 4H). Calcd for C22H26ClN3O: C 68.83, H 6.83, N 10.95; Found: C 69.12, H
6.86, N 10.72.
4.1.21. 2-(4-(4-(4-Chlorophenyl)piperazin-1-yl)butyl)benzo[d]oxazole, 20—Yield
70%, mp 127–129 °C 1H NMR (CDCl3): δ 7.68–7.65 (m, 1H), 7.49–7.46 (m, 1H), 7.31–
7.28 (m, 2H), 7.19 (d, J = 9.3 Hz, 2H), 6.82 (d, J = 9.0 Hz, 2H), 3.14 (t, J = 4.8 Hz, 4H),
2.98 (t, J = 7.5 Hz, 2H), 2.58 (t, J = 4.8 Hz, 4H), 2.45 (t, J = 7.5 Hz, 2H), 1.98–1.93 (m, 2H),
1.72–1.62 (m, 2H). Calcd for C21H24ClN3O 0.18 H2O: C 67.60, H 6.48, N 11.26; Found: C
67.69, H 6.61, N 10.98.
4.1.22. 2-(3-(4-(4-Chlorophenyl)piperazin-1-yl)propyl)benzo[d]oxazole, 21—
Yield 37%, mp 98–99 °C 1H NMR (CDCl3): δ 7.68–7.65 (m, 1H), 7.49–7.46 (m, 1H), 7.30–
7.28 (m, 2H), 7.18 (d, J = 9.3 Hz, 2H), 6.80 (d, J = 9.0 Hz, 2H), 3.09 (t, J = 5.1 Hz, 4H),
3.01 (t, J = 7.8 Hz, 2H), 2.59 (t, J = 5.1 Hz, 4H), 2.53 (t, J = 6.9 Hz, 2H), 2.14–2.09 (m, 2H).
Calcd for C20H22ClN3O: C 67.50, H 6.23, N 11.81; Found: C 67.28, H 6.35, N 11.56.
4.1.23. 2-(2-(4-(4-Chlorophenyl)piperazin-1-yl)ethyl)benzo[d]oxazole, 22—Yield
58%, mp 110–112 °C 1H NMR (CDCl3): δ 7.69–7.66 (m, 1H), 7.52–7.47 (m, 1H), 7.32–
7.30 (m, 2H), 7.19 (d, J = 9.3 Hz, 2H), 6.83 (d, J = 9.0 Hz, 2H), 3.18–3.14 (m, 6H), 3.01 (t,
J = 6.9 Hz, 2H), 2.70 (t, J = 5.1 Hz, 4H). Cacld for C19H20ClN3O: C 66.76, H 5.90, N
12.29; Found C 67.06, N 5.97, H 11.90.
4.1.24. General Method for Tosylated alkyl benzofurans—The method reported in
Bakunova et al,16 was followed to construct the benzofuran moiety. A mixture of 2-
Iodophenol (3g, 1eq), alkyl-1-yn-1-ol (1.1eq), and copper (I) oxide (1.36 g, 0.7eq) in dry
pyridine (15 mL) was stirred at 100–120 °C overnight. The mixture was allowed to cool to
rt, diluted with EtOAc (50 mL), filtered through celite and concentrated. The residue was
dissolved in EtOAc (100 mL), washed with 2 M HCl (50 mL) and brine (100 mL), dried
over Na2SO4, and concentrated. The residue was, then, dissolved in CH2Cl2 (10 mL) and
TsCl (1.1eq) and Et3N (1.4eq) were added at rt while stirring overnight. The solution was
diluted with EtOAc (50 mL), washed with H2O (3 × 50 mL) and brine (50 mL). The pooled
organic solvent was dried (Na2SO4), concentrated under reduced pressure and purified using
column chromatography with hexane:EtOAc (7:3) as the eluent.
4.1.25. General Procedure for Benzofuran Coupling—To a stirred solution of
CH3CN (10 mL) and Et3N (2 eq), the appropriate haloalkylbenzofuran (1eq) and an
arylcycloalkylamine (1.1eq) were added and refluxed overnight. The solution was allowed
to cool to rt, diluted with EtOAc (50 mL) and washed with H2O and brine, dried over
Na2SO4 and concentrated under reduced pressure. The residue was purified using column
chromatography with hexane:EtOAc (6:4) as the eluent to afford an orange-yellow solid.
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93%, mp 166.6 – 168.2 °C 1H NMR (CDCl3): δ 7.49 (dd, J = 4.5, 4.5 Hz, 1H), 7.42 (d, J =
12.0 Hz, 1H), 7.24 (m, 4H), 6.87 (d, J = 9.0 Hz, 2H), 6.46 (s, 1H), 3.19 (t, J = 15 Hz, 4H),
3.03 (t, J = 9.0 Hz, 2H), 3.85 (t, J = 9.0 Hz, 2H), 2.70 (t, J = 15 Hz, 4H). 13C NMR (CDCl3):
δ 157.4, 154.3, 149.98, 128.98, 124.3, 123.2, 122.2, 120.2, 117.3, 110.07, 102.3, 56.1, 52.8,
49.3, 26.2. Calcd for C20H21ClN2O: C 70.48, H 6.21, N 8.22; Found: C 70.63, H 6.30, N
8.25.
4.1.27. 1-(3-(Benzofuran-2-yl)propyl)-4-(4-chlorophenyl)piperazine, 24—Yield
90%, mp 84.8 – 85.9 °C 1H NMR (CDCl3): δ 7.49 (dd, J = 6.0, 6.0 Hz, 1H), 7.41 (d, J =
12.0 Hz, 1H), 7.19 (m, 4H), 6.84 (d, J = 9.0 Hz, 2H), 6.41 (s, 1H), 3.15 (t, J = 15 Hz, 4H),
2.83 (t, J = 9.0 Hz, 2H), 2.62 (t, J = 12.0 Hz, 2H), 2.49 (t, J = 9 Hz, 4H), 1.97 (m, 2H). 13C
NMR (CDCl3): δ 158.5, 154.5, 149.98, 128.94, 124.25, 123.21, 122.47, 120.24, 117.22,
110.75, 102.1, 57.66, 53.05, 49.11, 26.32, 24.88. Calcd for C21H23ClN2O·0.3H2O: C 70.01,
H 6.43, N 7.78; Found: C 69.9, H 6.41, N 7.42.
4.1.28. 2-(3-(Benzofuran-2-yl)propyl)-5-(4-chlorophenyl)-2,5-
diazabicyclo[2.2.1]heptane, 25—Yield 70%, mp 88.1 – 89.5 °C. 1H NMR (CDCl3): δ
7.46 (dd, J = 5.4, 4.5 Hz,1H), 7.19 (m, 1H), 7.17 (m, 1H), 7.13 (d, J = 9.6 Hz, 2H), 6.45 (d,
J = 12.0 Hz, 2H), 6.35 (s, 1H), 4.18 (br s, 1H), 3.57 (br s, 1H), 3.35 (dd, J = 4.5, 3.3 Hz,
1H,), 3.22 (d, J = 9 Hz, 1H), 2.99 (dd, J = 4.5, 4.5 Hz, 1H), 2.78 (t, J = 9.0 Hz, 2H), 2.55 (m,
4H), 1.94 (t, J = 9 Hz, 2H), 1.84 (t, J = 9 Hz, 2H). 13C NMR (CDCl3): δ 158.9, 154.2, 145.7,
128.9, 123.3, 122.2, 120.9, 120.05, 113.8, 110.6, 102.1, 61.7, 57.7, 56.9, 52.05, 36.3, 27.1,
26.01. Calcd for C22H23ClN2O: C 72.02, H 6.32, N 7.64; Found: C 71.75, H 6.38, N 7.51.
4.1.29. 1-(3-(Benzofuran-2-yl)propyl)-4-(4-chlorophenyl)-1,4-diazepane
dihydrochloride, 26—Yield 89%, mp 138.1 – 139.9 °C. 1H NMR (CDCl3): δ 7.46 (dd, J
= 6.0, 4.8 Hz, 1H), 7.39 (dd, J = 6.0Hz, 3.3 Hz, 1H), 7.14–7.22 (m, 2H), 7.12 (d, J = 7.2 Hz,
2H), 6.57 (d, J = 6.0 Hz, 2H), 6.35 (s, 1H), 3.53 (t, J = 6.0 Hz, 2H), 3.44 (t, J = 9.0 Hz, 2H),
2.73–2.81 (m, 4H), 2.66 (t, J = 6.0 Hz, 2H), 2.58 (t, J = 6.0 Hz, 2H), 1.91–2.00 (m, 4H).
Calcd for C22H27Cl3N2O·0.5H2O: C 63.77, H 6.32, N 6.76; Found: C 63.78, H 6.35, N
6.61.
4.1.30. 2-(3-Chloropropyl)benzo[d]thiazole, 48—A mixture of 2-aminobenzenethiol
(10 g, 80 mmol) and 4-chlorobutyl chloride (14 g, 99 mmol) in toluene (100 mL) was stirred
for 48 h at rt. The mixture was diluted with EtOAc (300 mL) and washed with saturated aq
NaHCO3 (2 × 100 mL). The organic layer was dried with Na2SO4, and filtered. The filtrate
was concentrated in vacuo, followed by chromatography on silica gel to afford 2-(3-
chloropropyl)benzo[d]thiazole (13.5 g, 80%.) as an oil. 1H NMR (CDCl3): δ 7.98 (d, J = 8.4
Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 8.4 Hz, 1H), 7.37 (t, J = 8.4 Hz, 1H), 3.69 (t, J
= 6.6 Hz, 2H), 3.30 (t, J = 7.5 Hz, 2H), 2.34–2.42 (m, 2H).
4.1.31. 2-(3-(4-(Pyrimidin-2-yl)piperazin-1-yl)propyl)benzo[d]thiazole
trihydrobromide, 28—A mixture of 2-(3-chloropropyl)benzothiazole (1.5 g, 7.08 mmol),
2-(piperazin-1-yl)pyrimidine dihydrochloride (1.6 g, 6.7 mmol), KI (200 mg), K2CO3 (1.2 g,
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8.7 mmol) in DME (10 mL) was heated to reflux under N2 for 12 h. The mixture was diluted
with EtOAc (400 ml) and washed with brine (50 mL). The organic layer was dried over
Na2SO4, and filtered. The filtrate was concentrated in vacuo to dryness and the residue was
column chromatographed on silica gel to afford 2-[3-(4-pyrimidin-2-yl-piperazin-1-
yl)propyl]benzothiazole, 28. The product was converted into the HBr salt, and recrystallized
from MeOH-Et2O (865 mg, 21%), mp > 260 °C. 1H NMR (DMSO-d6): δ 12.08 (brs, 2H),
10.13 (brs, 1H), 8.45 (d, J = 4.5 Hz, 2H), 8.07 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 8.1 Hz, 1H),
7.48 (dt, J = 1.5, 8.1 Hz, 1H), 7.40 (dt, J = 1.5, 8.1 Hz, 1H), 6.78 (t, J = 4.5 Hz, 1H), 4.68 (d,
J = 14.1 Hz, 2H), 3.63 (d, J = 14.1 Hz, 2H), 3.35–3.44 (m, 2H), 3.20–3.31 (m, 4H), 3.04–
3.14 (m, 2H), 2.25–2.35 (m, 2H). Calcd for C18H24Br3N5S: C 37.13, H 4.16, N 12.03;
Found: C 37.22, H 4.11, N 12.01.
4.2. Receptor binding studies
Binding affinities (Ki, nM) reported in Tables 1–4 were conducted by the National Institute
of Mental Health Psychoactive Drug Screening Program (NIMH-PDSP) unless otherwise
stated. Details of the methods and the radioligands used for the binding assays at each
receptor were previously reported.22
Acknowledgments
This work was supported by NIH grant # 5SC1GM088451-01-04 and a Title III Grant to Florida A&M University.
The work was also supported in part by RCMI grant # 5 G12 MD007582-30 and the Pharmaceutical Research
Center NIH/NCRR grant # 1C06-RR12512-01.
References
1. a) Seeman P, Van Tol HHM. Trends Pharmacol Sci. 1994; 15:264. [PubMed: 7940991] b) Van Tol
HHM, Burnzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Nature. 1991;
350:610. [PubMed: 1840645] c) Beaulieu J-M, Gainetdinov RR. Pharmacol Rev. 2011; 63:182.
[PubMed: 21303898]
2. a) Bergauer M, Hübner H, Gmeiner P. Bioorg Med Chem Lett. 2002; 12:1937. [PubMed:
12113813] b) McGough JJ. Pharmacogenomics. 2012; 13:365. [PubMed: 22379991] c) Lynn DE,
Lubke G, Yang M, McCracken JT, McGough JJ, Ishii J, Loo SK, Nelson SF, Smalley SL. Am J
Psychiatry. 2005; 162:906. [PubMed: 15863792]
3. Ukai M, Mitsunaga H. Methods Find Exp Clin Pharmacol. 2005; 27:645. [PubMed: 16357950]
4. a) Yan Y, Mizuno T, Nitta A, Yamada K, Nabeshima T. Ann NY Acad Sci. 2004; 1025:274.
[PubMed: 15542727] b) Yan Y, Nitta A, Mizuno T, Nakajima A, Yamada K, Nabeshima T. Behav
Brain Res. 2006; 173:39. [PubMed: 16857277]
5. Mamiya T, Matsumura T, Ukai M. Ann NY Acad Sci. 2004; 1025:424. [PubMed: 15542745]
6. Yan Y, Pushparaj A, Le Strat Y, Gamaleddin I, Barnes C, Justinova Z, Goldberg SR, Le Foll B.
Neuropsychopharmacology. 2012; 37:685. [PubMed: 22030716]
7. a) Sanna F, Corda MG, Melis MR, Piludu MA, Löber S, Hübner H, Gmeiner P, Argiolas A, Giorgi
O. Pharmacol Biochem Behav. 2013; 109:59. [PubMed: 23664901] b) Patel MV, Kolasa T, Mortell
K, Matulenko MA, Hakeem AA, Rohde JJ, Nelson SL, Cowart MD, Nakane M, Miller LN, Uchic
ME, Terranova MA, El-Kouhen OF, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR,
Chang R, Martino BR, Wetter JM, Marsh KC, Martin R, Darbyshire JF, Gintant G, Hsieh GC,
Moreland RB, Sullivan JP, Brioni JD, Stewart AO. J Med Chem. 2006; 49:7450. [PubMed:
17149874] c) Kolasa T, Matulenko MA, Hakeem AA, Patel MV, Mortell K, Bhatia P, Henry R,
Nakane M, Hsieh GC, Terranova MA, Uchic ME, Miller LN, Chang R, Donnelly-Roberts DL,
Namovic MT, Hollingsworth PR, Martino B, El Kouhen O, Marsh KC, Wetter JM, Moreland RB,
Brioni JD, Stewart AO. J Med Chem. 2006; 49:5093. [PubMed: 16913699]
Sampson et al. Page 14






















8. a) Galvez-Ruiz A, Arishi N. Saudi J Ophthalmol. 2013; 27:241–6. [PubMed: 24409087] b) Byoun
H-S, Lee Y-J, Yi H-J. J Korean Neurosurg Soc. 2010; 47:210–212. [PubMed: 20379474] c) Buxton
N, Flannery T, Wild D, Bassi S. Br J Neurosurg. 2001; 15:347–349. [PubMed: 11599452] Egan
RA, Pomeranz H. Neurology. 2002; 59:293–294. [PubMed: 12136078] d) Habek M, Petravic D.
Clin Neuropharmacol. 2006; 29:165–167. [PubMed: 16772819] e) Martí I, Martí Massó JF.
Neurology. 2004; 63:534. [PubMed: 15304588] f) Monastero R, Pipia C, Camarda LK, Camarda R.
J Neurol. 2001; 248:141–142. [PubMed: 11284133]
9. Sood P, Idris NF, Cole S, Grayson B, Neill JC, Young AM. J Psychopharmacol. 2011; 25:792–800.
[PubMed: 21088042]
10. a) Peprah K, Zhu XY, Eyunni SVK, Setola V, Roth BL, Ablordeppey SY. Bioorg Med Chem.
2012; 20:1291. [PubMed: 22245230] b) Peprah K, Zhu XY, Eyunni SVK, Etukala JR, Setola V,
Roth BL, Ablordeppey SY. Bioorg Med Chem. 2012; 20:1671. [PubMed: 22336245]
11. Sikazwe DMN, Nkansah NT, Altundas R, Zhu XY, Roth BL, Ablordeppey SY. Bioorg Med
Chem. 2009; 17:1716. [PubMed: 19155177]
12. Ablordeppey SY, Altundas R, Bricker B, Zhu XY, Eyunni VKSK, Jackson T, Khan A, Roth BL.
Bioorg Med Chem. 2008; 16:7291. [PubMed: 18595716]
13. Vaidya T, Eisenberg R, Frontier AJ. ChemCatChem. 2011; 3:1531.
14. Yamamura S, Nishiyama S. Comp Org Syn. 1991; 8:309.
15. Zhu XY, Etukala JR, Eyunni SVK, Setola V, Roth BL, Ablordeppey SY. Eur J Med Chem. 2012;
53:124. [PubMed: 22520153]
16. Bakunova SM, Bakunov SA, Wenzler T, Barszcz T, Werbovetz KA, Brun R, Hall JE, Tidwell RR.
J Med Chem. 2007; 50:5807. [PubMed: 17948982]
17. http://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking/
[accessed 2-10-2014]
18. U.S. Department of Health and Human Services. A Report of the Surgeon General: How Tobacco
Smoke Causes Disease: What It Means to You. U.S. Department of Health and Human Services,
Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and
Health Promotion, Office on Smoking and Health; 2010. http://www.cdc.gov/tobacco/
datastatistics/sgr/2010/consumerbooklet/pdfs/consumer.pdf[accessed 2-10-2014]
19. a) Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, Gervais A, O’Loughlin J,
Paradis G, Rinfret S, Pilote L. CMAJ. 2008; 179:135. [PubMed: 18625984] b) Singh S, Loke YK,
Spangler JG, Furberg CD. CMAJ. 2011; 183:1359. [PubMed: 21727225] c) Goldstein MG. J Clin
Psychiatry. 1998; 59:66. [PubMed: 9554323] d) Hays JT, Ebbert JO, Sood A. Mayo Clin Proc.
2009; 84:730. [PubMed: 19648390]
20. Abdelfattah MAO, Lehman J, Abadi AH. Bioorg Med Chem Lett. 2013; 23:5077. [PubMed:
23920439]
21. Kulagowski JJ, Broughton HB, Curtis NR, Mawer IM, Ridgill MP, Baker R, Emms F, Freedman
SB, Marwood R, Patel S, Patel S, Ragan CI, Leeson PD. J Med Chem. 1996; 39:1941. [PubMed:
8642550]
22. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R.
Neuropsychopharmacology. 2003; 28:1400. [PubMed: 12784105]
Sampson et al. Page 15






















Scheme 1. Synthesis of 4-chlorophenylpiperazine analogs, 8–10
Reagents and conditions: i) HMTA, Ac2O, Reflux; ii) Conc. H2SO4, 60°C; iii) a) Ethylene
glycol, TsOH, Reflux, 48 h; b) NaBH4, MeOH; iv) Zn/HgCl2, Conc. HCl, Toluene; v) KI,
K2CO3, DME, 90°C, 4-(4-chlorophenyl)piperazine, 12 h; vi) TsOH, MeOH, rt
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Scheme 2. Synthesis of heteroaryl piperazine analogs. 11–16
Reagents and conditions: i) KI, K2CO3, iPrOH or DME, Reflux; ii) MsCl/TsCl, Et3N, DCM,
rt; iii) KI, K2CO3, DME, 90°C, heteroaryl piperazine, 12 h.
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Scheme 3. Synthesis of benzoxazole derivatives, 19–22
Reagents and Conditions: (i) EtOAc, TEA, Reflux; (ii) PPA, 110°C; (iii) CH3CN, K2CO3,
KI, Reflux.
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Scheme 4. Synthesis of benzofuran analogs, 23–26
Reagents and conditions: (i) An appropriate alkyl-1-yn-1-ol, Cu2O, pyridine, 100°C, 15h (ii)
TosylCl, NEt3, CH2Cl2, rt, overnight; (iii) NHR2 [Aryl piperazine or related analog], ACN,
NEt3, 60°C, reflux.
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Scheme 5. Synthesis of benzothiazole analog, 28
Reagents and conditions: (i) Toluene, rt; (ii) KI, K2CO3, CH3CN, reflux.
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Known D4 selective Ligands with a Piperazine Pharmacophore
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Benzothiazole, Benzoxazole and Benzofuran Analogs
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